Wound care co Polyheal sees continued good trial results

Twice as many chronic wounds were completely closed in patients treated with Polyheal-1, compared with the patients in the control group.

Wound care treatment developer Polyheal Ltd. today announced the final results of the Phase IV clinical trial of its leading product, Polyheal-1.

A Phase IV clinical trial is a post-marketing study to gain better understanding of a treatment. The double blind trial included 66 patients with third and fourth-degree chronic wounds at five medical centers in Israel. The patients were divided into two groups, one of which received Polyheal-1 and the other which received a standard treatment (the control group), over a four-week period. The two groups then both received a standard treatment for eight more weeks.

The trial results found that 65% of the patients treated with Polyheal-1 met the primary endpoint - covering of the wound with a granulated layer - compared with 19% of the patients in the control group. After four weeks, the area of the wound was reduced by an average of 40% in patients treated with Polyheal-1, compared with an average of 15% among patients in the control group. The difference persisted at the end of the additional eight-week period.

At the end of the additional eight-week period, twice as many chronic wounds were completely closed in patients treated with Polyheal-1, compared with the patients in the control group.

The analysis of certain sub-groups found that in the subgroup of 24 patients suffering from venous chronic wounds, 73% of the patients treated with Polyheal-1 met the trial's primary endpoint. In the sub-group of 10 patients with severe wounds, such as where the bone was exposed, 73% of the patients treated with Polyheal-1 met the trial's primary endpoint. In both sub-groups, none of the patients in the control group achieved the primary endpoint. At the end of the additional eight-week period, five times as many wounds in these two sub-groups were completely closed, compared with the patients in the control group.

Polyheal’s patented wound management technology uses chemically inert, non-biodegradable, charged synthetic microspheres, to initiate and promote the complex wound healing process, without the need of additional drugs. The company claims that the market for chronic wound treatment is $7 billion annually.

Nochi Dankner-controlled IDB Holding Corp. Ltd. (TASE:IDBH) life sciences investment unit Clal Biotechnology Industries Ltd. (TASE: CBI) owns 40% of Polyheal.

Published by Globes [online], Israel business news - www.globes-online.com - on February 4, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס